<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67272">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02089139</url>
  </required_header>
  <id_info>
    <org_study_id>I13009</org_study_id>
    <nct_id>NCT02089139</nct_id>
  </id_info>
  <brief_title>Treatment of Discogenic Back Pain</brief_title>
  <acronym>EGID</acronym>
  <official_title>Intradiscal Injection of Gelified Ethanol for the Treatment of Discogenic Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GELSCOM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Discogenic low back pain is the most common form of chronic low back pain. Its diagnosis is
      mainly based on MR imaging, showing MODIC I or II changes in patients with concordant
      symptomatology. The treatment of discogenic low back pain is nevertheless difficult:
      intradiscal therapies (corticosteroids, methylene blue, radiofrequency) have a limited
      efficacy, and surgical procedures (arthrodesis or disc replacement) are a final recourse
      with notable risk of side-effects.

      In this study, the efficacy of intradiscal injection of gelified ethanol (DiscoGel) in
      patients with disabling discogenic pain is assessed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>Six months after the procedure.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean pain intensity score on a Visual Analog Scale (VAS), six months after the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS),</measure>
    <time_frame>one month, three months, six months and 1 year after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean pain intensity score on Visual Analog Scale (VAS), one month, three months, six months and 1 year after the procedure ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>one month, three months, six months and 1 year after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Oswestry Disability Index (ODI) one month, three months, six months and 1 year after the procedure ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euroqol score</measure>
    <time_frame>month, three months, six months and 1 year after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of the quality of life with Euroqol score (EQ-5D) one month, three months, six months and 1 year after the procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Discogenic Back Pain</condition>
  <arm_group>
    <arm_group_label>DISCOGEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous intradiscal injection of  Discogel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to: medications (analgesics, NSAIDs, muscle relaxants), physical therapy, manual techniques, transcutaneous electrical nerve stimulation (TENS), blocks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Discogel</intervention_name>
    <description>DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)</description>
    <arm_group_label>DISCOGEL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional treatment</intervention_name>
    <description>Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:
medications (analgesics, NSAIDs, muscle relaxants),
physical therapy,
manual techniques,
transcutaneous electrical nerve stimulation (TENS),
blocks</description>
    <arm_group_label>DISCOGEL</arm_group_label>
    <arm_group_label>conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MR imaging : MODIC 1or MODIC 2 changes limited to one single lumbar disc;

          -  X rays: normal disc height, no instability;

          -  Back pain for at least 3 months, without argument for another etiology;

          -  Mean pain on 5 days VAS ≥ 5

        Exclusion Criteria:

          -  age &lt;18 years or &gt; 50 ; concomitant radicular pain ;

          -  psychiatric pathology that may modify the perception or the evolution of pain;

          -  MR imaging: multi-level discopathy, MODIC 3 changes;

          -  X ray: loss of disc height &gt; 50%, segmental instability;

          -  previous history of lumbar surgery with or without instrumentation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CAIRE François, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caire François, MD</last_name>
    <phone>05 55 05 65 21</phone>
    <email>francois.caire@chu-limoges.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>CAIRE François, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Back pain</keyword>
  <keyword>Discogel</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
